-
Mashup Score: 0Allo-HSCT Consolidation Appears Beneficial for Older AML Patients - 10 hour(s) ago
A phase 3 trial confirms “the potent anti-leukemic effect” of consolidation with allogeneic transplant in older patients with acute myeloid leukemia, according to researchers.
Source: www.cancertherapyadvisor.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 6
IN8bio Announces FDA Guidance for Registrational Trial of INB-100 as 100% of AML Patients remain in Complete Remission …
Source: www.globenewswire.comCategories: General Medicine News, Oncologists1Tweet-
🚨 NEWS 🚨 @US_FDA provides guidance for registrational trial of INB-100, an allogeneic gamma-delta T cell therapy, as a post-transplant maintenance therapy in patients with AML. The filing for IND approval is anticipated in Q1 2025. https://t.co/gnvueiLL7d #leusm #AMLsm https://t.co/WsEiDS0L5i
-
-
Mashup Score: 4SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to SLS009 for the Treatment of Pediatric Acute Myeloid Leukemia - 6 month(s) ago
– Acute Myeloid Leukemia (AML) is the Second Most Common Hematological Malignancy in Children Often Associated with Poorer Prognosis Compared to Other…
Source: www.globenewswire.comCategories: General Medicine News, Oncologists1Tweet-
🚨 NEWS 🚨 @US_FDA grants Rare Pediatric Disease Designation to SLS009, a highly selective CDK9 inhibitor, for the treatment of pediatric AML. Enrollment for pediatric patients in the ongoing phase II trial (NCT04588922) is now open. https://t.co/Qjp5WXhlav #leusm #AMLsm https://t.co/hFTe8vkV8J
-
-
Mashup Score: 3The Pre-MEASURE study: How does pretransplant IDH1 and IDH2 MRD affect posttransplant outcomes in patients with AML? - 8 month(s) ago
The AML Hub spoke to Gege Gui, National Institutes of Health, Maryland, US. We asked, How does pretransplant IDH1 and IDH2 MRD affect posttransplant outcomes in patients with AML?
Source: aml-hub.comCategories: General Medicine News, Onc News and JournalsTweet-
The AML Hub spoke to Gege Gui, National Institutes of Health, Maryland, US. We asked, How does pretransplant IDH1 and IDH2 MRD affect posttransplant outcomes in patients with AML? Watch here 👉 https://t.co/Bv2Z9Plaz9 #leusm #AMLsm
-
-
Mashup Score: 5Validation of automated semiconductor-based NGS in myeloid neoplasms - 9 month(s) ago
Here, we summarize a validation of the Oncomine Myeloid Assay GX v2 in myeloid malignancies published by Zbieranski and Insuasti-Beltran.1 in The Journal of Molecular Diagnostics.
Source: aml-hub.comCategories: General Medicine News, Onc News and JournalsTweet-
Is automated semiconductor-based NGS viable in AML? Read our summary of a validation of the Oncomine Myeloid Assay GX v2 in myeloid malignancies here: https://t.co/7GXROgl7td #leusm #AMLsm https://t.co/8qlseNe2kd
-
-
Mashup Score: 6Visual abstract | Phase III randomized, open-label study of guadecitabine vs treatment choice in R/R AML: ASTRAL-2 - 10 month(s) ago
The AML Hub is pleased to present a visual abstract summarizing results from the phase III ASTRAL-2 trial assessing guadecitabine vs standard-of-care treatment in patients with R/R AML.
Source: aml-hub.comCategories: General Medicine News, Onc News and JournalsTweet-
Is guadecitabine an effective treatment for patients with relapsed/refractory acute myeloid leukemia? Check out our visual abstract of the phase III ASTRAL-2 trial here: https://t.co/GED5pJ3Lr4 #leusm #AMLsm https://t.co/7Gtj360h2e
-
-
Mashup Score: 13
Here we summarize results from the UK AML19 trial, published by Russell et al.1 in Journal of Clinical Oncology, which aimed to determine the optimal induction chemotherapy regimen in younger patients with newly diagnosed AML without adverse risk cytogenetics.
Source: aml-hub.comCategories: General Medicine News, Onc News and JournalsTweet-
What is the optimal induction chemotherapy regimen for younger patients with newly diagnosed acute myeloid leukemia without adverse risk cytogenetics? 👉Read our summary of results from the UK AML19 trial here: https://t.co/PJIzZRTYLh #leusm #AMLsm
-
-
Mashup Score: 12
Here, we summarize results from a phase I/II trial evaluating the safety and efficacy of azacitidine, venetoclax, and gilteritinib in patients with newly diagnosed and R/R FLT3-mutated AML, published by Short et al.1 in Journal of Clinical Oncology.
Source: aml-hub.comCategories: General Medicine News, Onc News and JournalsTweet-
Is the triplet combination of azacitidine + venetoclax + gilteritinib effective in patients with R/R or ND FLT3-mutated AML who are ineligible for intensive chemotherapy? Read our summary of the results from a phase I/II trial here: https://t.co/BXVFYQw8OI #leusm #AMLsm https://t.co/z9n1JKr5yP
-
-
Mashup Score: 4The latest on oral azacitidine maintenance therapy in AML - 11 month(s) ago
Here, we summarize an article by Ravandi et al. and presentations from ASH 2023 by Daniel Lopes De Menezes and Alice Mims on oral azacitidine maintenance treatment following intensive chemotherapy in patients with AML.
Source: aml-hub.comCategories: General Medicine News, Onc News and JournalsTweet-
What are the latest updates on oral azacitidine maintenance therapy for the treatment of patients with acute myeloid leukemia? Find out here 👉 https://t.co/MMMJGJN1c1. #leusm #AMLsm https://t.co/nx1nakjmNT
-
-
Mashup Score: 6
Here, we summarize key points from a recent “How I Treat” article by Thor et al., discussing the treatment of patients with relapse/refractory acute myeloid leukemia.
Source: aml-hub.comCategories: General Medicine News, Onc News and JournalsTweet-
Read our summary of a “How I Treat” article, discussing the treatment of patients with relapsed/refractory acute myeloid leukemia. 👉 https://t.co/3hTdItf0yU #leusm #AMLsm https://t.co/b17EvME5r0
-
Allo-HSCT consolidation improved LFS when compared to other consolidation regimens in older patients with AML in CR1. Findings published in @Haematologica. https://t.co/jeOiL7w59r #leusm #amlsm